| Style | Citing Format |
|---|---|
| MLA | Haghiri A, et al.. "Systematic Review and Meta-Analysis of Hypofractionated and Conventional Fractionated Radiotherapy on Survival in Breast Cancer Patients." Immunopathologia Persa, vol. 12, no. 2, 2026, pp. -. |
| APA | Haghiri A, Zebardast J, Akbari A, Kalantari Khandani M, Shakiba M, Shahrabi Farahani N, Akbari M E, Eslami M (2026). Systematic Review and Meta-Analysis of Hypofractionated and Conventional Fractionated Radiotherapy on Survival in Breast Cancer Patients. Immunopathologia Persa, 12(2), -. |
| Chicago | Haghiri A, Zebardast J, Akbari A, Kalantari Khandani M, Shakiba M, Shahrabi Farahani N, Akbari M E, Eslami M. "Systematic Review and Meta-Analysis of Hypofractionated and Conventional Fractionated Radiotherapy on Survival in Breast Cancer Patients." Immunopathologia Persa 12, no. 2 (2026): -. |
| Harvard | Haghiri A et al. (2026) 'Systematic Review and Meta-Analysis of Hypofractionated and Conventional Fractionated Radiotherapy on Survival in Breast Cancer Patients', Immunopathologia Persa, 12(2), pp. -. |
| Vancouver | Haghiri A, Zebardast J, Akbari A, Kalantari Khandani M, Shakiba M, Shahrabi Farahani N, et al.. Systematic Review and Meta-Analysis of Hypofractionated and Conventional Fractionated Radiotherapy on Survival in Breast Cancer Patients. Immunopathologia Persa. 2026;12(2):-. |
| BibTex | @article{ author = {Haghiri A and Zebardast J and Akbari A and Kalantari Khandani M and Shakiba M and Shahrabi Farahani N and Akbari M E and Eslami M}, title = {Systematic Review and Meta-Analysis of Hypofractionated and Conventional Fractionated Radiotherapy on Survival in Breast Cancer Patients}, journal = {Immunopathologia Persa}, volume = {12}, number = {2}, pages = {-}, year = {2026} } |
| RIS | TY - JOUR AU - Haghiri A AU - Zebardast J AU - Akbari A AU - Kalantari Khandani M AU - Shakiba M AU - Shahrabi Farahani N AU - Akbari M E AU - Eslami M TI - Systematic Review and Meta-Analysis of Hypofractionated and Conventional Fractionated Radiotherapy on Survival in Breast Cancer Patients JO - Immunopathologia Persa VL - 12 IS - 2 SP - EP - PY - 2026 ER - |